

Sukhmani K Padda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6554781/publications.pdf>

Version: 2024-02-01

38
papers

2,343
citations

394421

19
h-index

345221

36
g-index

38
all docs

38
docs citations

38
times ranked

3710
citing authors

#	ARTICLE	IF	CITATIONS
1	A phase 1b study of erlotinib and momelotinib for the treatment of EGFR-mutated, tyrosine kinase inhibitor-naïve metastatic non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 105-115.	2.3	10
2	Diffuse idiopathic pulmonary neuroendocrine cell hyperplasia: clinical characteristics and progression to carcinoid tumour. <i>European Respiratory Journal</i> , 2022, 59, 2101058.	6.7	10
3	Afatinib After Progression on Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer. <i>Cancer Treatment and Research Communications</i> , 2022, 30, 100497.	1.7	4
4	Lung Neuroendocrine Tumors: How Does Molecular Profiling Help?. <i>Current Oncology Reports</i> , 2022, 24, 819-824.	4.0	4
5	Management of Stage III Non-“Small-Cell Lung Cancer: ASCO Guideline. <i>Journal of Clinical Oncology</i> , 2022, 40, 1356-1384.	1.6	104
6	Autoimmune Disease in Patients With Advanced Thymic Epithelial Tumors. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100323.	1.1	2
7	Combination of Immunotherapy and Antiangiogenic Therapy in Cancer-“a Rational Approach. <i>Journal of Thoracic Oncology</i> , 2021, 16, 178-182.	1.1	8
8	Clinical Implications of KEAP1-NFE2L2 Mutations in NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 395-403.	1.1	33
9	Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response Monitoring. <i>Clinical Chemistry</i> , 2021, 67, 534-542.	3.2	14
10	Myocarditis Surveillance With High-Sensitivity Troponin I During Cancer Treatment With Immune Checkpoint Inhibitors. <i>JACC: CardioOncology</i> , 2021, 3, 137-139.	4.0	55
11	Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study. <i>Lung Cancer</i> , 2021, 154, 186-194.	2.0	3
12	Role of Consolidation Durvalumab in Patients With EGFR- and HER2-Mutant Unresectable Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 868-872.	1.1	42
13	Durvalumab for Stage III EGFR-Mutated NSCLC After Definitive Chemoradiotherapy. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1030-1041.	1.1	79
14	Genomic clustering analysis identifies molecular subtypes of thymic epithelial tumors independent of World Health Organization histologic type. <i>Oncotarget</i> , 2021, 12, 1178-1186.	1.8	6
15	Radiological tumour classification across imaging modality and histology. <i>Nature Machine Intelligence</i> , 2021, 3, 787-798.	16.0	41
16	Pharmacovigilance Analysis of Cardiac Toxicities Associated With Targeted Therapies for Metastatic NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 2029-2039.	1.1	34
17	Advances in Treatment of Recurrent Small Cell Lung Cancer (SCLC): Insights for Optimizing Patient Outcomes from an Expert Roundtable Discussion. <i>Advances in Therapy</i> , 2021, 38, 5431-5451.	2.9	12
18	Computational Biological Modeling Identifies PD-(L)1 Immunotherapy Sensitivity Among Molecular Subgroups of KRAS-Mutated Non-“Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2021, 5, 153-162.	3.0	4

#	ARTICLE	IF	CITATIONS
19	Role of KEAP1/NFE2L2 Mutations in the Chemotherapeutic Response of Patients with Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 274-281.	7.0	75
20	Noninvasive Early Identification of Therapeutic Benefit from Immune Checkpoint Inhibition. <i>Cell</i> , 2020, 183, 363-376.e13.	28.9	206
21	Everolimus in the treatment of metastatic thymic epithelial tumors. <i>Lung Cancer</i> , 2020, 149, 97-102.	2.0	12
22	Commonwealth Neuroendocrine Tumour Research Collaboration and the North American Neuroendocrine Tumor Society Guidelines for the Diagnosis and Management of Patients With Lung Neuroendocrine Tumors: An International Collaborative Endorsement and Update of the 2015 European Neuroendocrine Tumor Society Expert Consensus Guidelines. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1577-1598.	1.1	58
23	Latest advances in management of small cell lung cancer and other neuroendocrine tumors of the lung. <i>Cancer Treatment and Research Communications</i> , 2020, 23, 100167.	1.7	6
24	RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer. <i>British Journal of Cancer</i> , 2019, 121, 211-217.	6.4	29
25	Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes. <i>Lung Cancer</i> , 2019, 133, 144-150.	2.0	90
26	Impact of KEAP1/NFE2L2/CUL3 mutations on duration of response to EGFR tyrosine kinase inhibitors in EGFR mutated non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 134, 42-45.	2.0	37
27	Epidermal Growth Factor Receptor Mutation Status Confers Survival Benefit in Patients with Non-Small-Cell Lung Cancer Undergoing Surgical Resection of Brain Metastases: A Retrospective Cohort Study. <i>World Neurosurgery</i> , 2019, 125, e487-e496.	1.3	5
28	First-in-Human, First-in-Class Phase I Trial of the Anti-CD47 Antibody Hu5F9-G4 in Patients With Advanced Cancers. <i>Journal of Clinical Oncology</i> , 2019, 37, 946-953.	1.6	377
29	Response to comment on "Impact of KRAS mutation subtype and concurrent pathogenic mutations on non-small cell lung cancer outcomes". <i>Lung Cancer</i> , 2019, 137, 159-160.	2.0	2
30	Resolution of Crizotinib-Associated Fulminant Hepatitis following Cessation of Treatment. <i>Case Reports in Hepatology</i> , 2018, 2018, 1-5.	0.7	6
31	Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling. <i>Cancer Discovery</i> , 2017, 7, 1394-1403.	9.4	701
32	Determinants of Complete Resection of Thymoma by Minimally Invasive and Open Thymectomy: Analysis of an International Registry. <i>Journal of Thoracic Oncology</i> , 2017, 12, 129-136.	1.1	62
33	Navigating the Landscape of Molecular Testing and Targeted Treatment of Non-Small Cell Lung Cancer. <i>Journal of the Advanced Practitioner in Oncology</i> , 2016, 7, 299-301.	0.4	0
34	Pruritus as a Paraneoplastic Symptom of Thymoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, e110-e112.	1.1	2
35	Diffuse High Intensity PD-L1 Staining in Thymic Epithelial Tumors. <i>Journal of Thoracic Oncology</i> , 2015, 10, 500-508.	1.1	129
36	Pemetrexed in patients with thymic malignancies previously treated with chemotherapy. <i>Lung Cancer</i> , 2015, 87, 34-38.	2.0	27

#	ARTICLE	IF	CITATIONS
37	Early-Stage Non-Small Cell Lung Cancer: Surgery, Stereotactic Radiosurgery, and Individualized Adjuvant Therapy. <i>Seminars in Oncology</i> , 2014, 41, 40-56.	2.2	46
38	Phase I and pharmacokinetic study of bexarotene in combination with gefitinib in the third-line treatment of non-small-cell lung cancer. <i>Anti-Cancer Drugs</i> , 2013, 24, 731-735.	1.4	8